

FOSUN PHARMA
复星医药

2023



1

2

3

4

5

6



1H23

1/2

▪
▪
▪

▪
▪
▪
▪

▪
▪
▪

▪
▪

▪
▪
▪
▪

1H23

2/2

	1H23	1H22			1H23	2022	
	213.95	213.48	}				
	106.97	97.7				148.85	162.41
	50.0%	45.8%					
	50.71	41.75			Sisram		
	23.7%	19.6%			PD-1		
	26.3%	26.2%					
	20.45	16.79				1.00	1.06
	9.6%	7.9%					
	21.34	18.27				0.79	0.85
	10.0%	8.6%					
	5.45	2.62					
	2.5%	1.2%			50.6%	49.5%	



® PD-1

1H23 5.56
3 ES-SCLC

ES-SCLC

PD-1

3 ES-SCLC


MAA EMA




2/2








&







2023 - 2024





2019 - 2022




Gland



API





MSCI-ESG




A

A

2023

BBB
2021

BB
2020



Environment

2022	EHS 2021-2026	EHS	EHS
	337,806	115.36	3.2%

Social

PQ	Argesun®	WHO
	3	1


Governance

ESG	ESG
10	2023 1




-


1



2,3



3



SCLC PD-1



1H23

5.56



(ASTCT)

r/r LBCL

2023 6 r/r LBCL

CAR-T

B LBCL 1.3
LBCL NHL 45.8%
NHL LBCL 4

500

2023 6

140

25

10,000

GMP

2023 6

60

90

FL

MZL

2021 8

r/r FL

Kite Pharma

CAR-T
/ B




Tecartus™ 2020 7

FDA
r/r ALL

/

MCL

2023










1

1,2

1









8.99%

1
2

2023







1H23 34 330

1,100

2000

FDA

2023 6

8,042

55,000

1,000

Ion

2019 Ion

FDA

2021 10


Ion

Ion






1





2011-2017

2,3




2018-2020

3




2021



600

2017 11

9.09

1,750




2022

21.45






1.11







87.41%













		®		
		®		
		®		
		®		
		®		

		®		
		®		
		®		
		®		
		®		
		®		

		®		
		®		
				
		®		
		®		
				

1/2

			/		IND	1	2	3	NDA
HLX10 ¹	+	PD-1			III 2022 11				
				/	2022 11	2022	FDA/EC	2023 1	
	+ +	PD-1			III 2023 1	2022 5			
	+	PD-1+VEGF							
	+HLX07	PD-1+EGFR			2022 1				
+HLX07 +	PD-1+EGFR +VEGF								
HLX07		EGFR							
HLX22									
HLX11	2	HER2			III 2022				
HLX05	3	EGFR							
HLX02	4	HER2			FDA 2020				

1 KG Bio 10
3
5 2023 7 31

2 Organon
4 Accord Cipla Jacobson mAbxience Eurofarma Abbott



1/2

		/		IND	1	2	3	NDA
FCN-437c		CDK4/6	1L					
			2L					
SAF-189		ALK/ROS1	ALK+					
			ROS1+					
HLX-208	-	BRAF	Erdheim-Chester ECD					
		BRAF+PD-1	BRAF V600E BRAF V600	LCH				
FCN-159		MEK	I					
YP01001		VEGFR						
FCN-338		BCL-2						

2/2

		/		IND	1	2	3	NDA
		TPO-R	ITP					
Tenapanor		NHE 3	(ESRD-HD)					
		P-CAB						
Tenapanor		NHE 3	(IBS-C)					
PA-824		-	XDR-TB / MDR-TB					
Opicapone		COMT						
Fortacin								

			IND	1	2	3	NDA
	/						
	/						
	/						
13							
24							
23							
	-						

2023 7 31

FOSUN

LOGO

Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and other related logos, like Fosun and , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.



www.fosunpharma.com